Dipeptidyl peptidase 4 concentration influenced by serum insulin levels rather than arterial stiffness index in type 2 diabetics

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 4, 2015, Pages 6236-6241

  Wu, Liming ^a   Gong, Qing ^a   Na, Risu ^a   Mao, Xudong ^a   Zheng, Xulei ^a   Liu, Qiaorui ^a   Ma, Cong ^a   Ding, Xin ^a   Sheng, Hongguang ^a   Liu, Zhiwen ^a  

^a Shanghai Sixth People's Hospital   (China)

Author keywords

Arterial stiffness index; Cholesterol; DPP 4; HDL; Insulin

Indexed keywords

C PEPTIDE; CHOLESTEROL; DIPEPTIDYL PEPTIDASE IV; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN;

ADULT; ARTERIAL STIFFNESS; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC OBESITY; DYSLIPIDEMIA; ECHOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN BLOOD LEVEL; LIPID METABOLISM; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; PROTEIN DEGRADATION;

EID: 84931275509     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC and Holman RR. Association of glycaemia with macrovascular and microvascular complica­tions of type 2 diabetes (UKPDS 35): prospec­tive observational study. BMJ 2000; 321: 405-412.
2. Toft-Nielsen MB, Madsbad S and Holst JJ. De­terminants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes. J Clin Endo­crinol Metab 2001; 86: 3853-3860.
3. Terasaki M, Nagashima M, Nohtomi K, Kohashi K, Tomoyasu M, Sinmura K, Nogi Y, Katayama Y, Sato K, Itoh F, Watanabe T and Hirano T. Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attribut­able to incretin’s actions in nondiabetic and diabetic apolipoprotein E-null mice. PLoS One 2013; 8: e70933.
4. Ta NN, Li Y, Schuyler CA, Lopes-Virella MF and Huang Y. DPP-4 (CD26) inhibitor alogliptin in­hibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histio­cytes. Atherosclerosis 2010; 213: 429-435.
5. Zeng Y, Li C, Guan M, Zheng Z, Li J, Xu W, Wang L, He F and Xue Y. The DPP-4 inhibitor sita­gliptin attenuates the progress of atherosclero­sis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms. Cardiovasc Diabetol 2014; 13: 32.
6. Barbieri M, Rizzo MR, Marfella R, Boccardi V, Esposito A, Pansini A and Paolisso G. De­creased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis 2013; 227: 349-354.
7. Katakami N, Mita T, Yoshii H, Onuma T, Kaneto H, Osonoi T, Shiraiwa T, Kosugi K, Umayahara Y, Yamamoto T, Yokoyama H, Kuribayashi N, Jinnouchi H, Gosho M, Watada H, Shimomura I; Collaborators on the Study of Preventive Ef­fects of Alogliptin on Diabetic Atherosclerosis Trial. Rationale, design, and baseline charac­teristics of a trial for the prevention of diabetic atherosclerosis using a DPP-4 inhibitor: the Study of Preventive Effects of Alogliptin on Dia­betic Atherosclerosis (SPEAD-A). J Atheroscler Thromb 2013; 20: 893-902.
8. Behme MT, Dupre J and McDonald TJ. Gluca­gon-like peptide 1 improved glycemic control in type 1 diabetes. BMC Endocr Disord 2003; 3: 3.
9. Dupre J, Behme MT, Hramiak IM, McFarlane P, Williamson MP, Zabel P and McDonald TJ. Glu­cagon-like peptide I reduces postprandial gly­cemic excursions in IDDM. Diabetes 1995; 44: 626-630.
10. Dicker D. DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors. Diabe­tes Care 2011; 34 Suppl 2: S276-278.